QQ客服 官方微博 反馈留言

	Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis
	Shen, Kaini; Zhang, Congli; Feng, Jun; Zhang, Lu; Cao, Xinxin; Zhou, Daobin; Li, Jian
	2018
卷号	132
ISSN号	0006-4971
DOI	10.1182/blood-2018-99-112407
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6349575
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Shen, Kaini,Zhang, Congli,Feng, Jun,et al. Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis[J],2018,132.
APA	Shen, Kaini.,Zhang, Congli.,Feng, Jun.,Zhang, Lu.,Cao, Xinxin.,...&Li, Jian.(2018).Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis.,132.
MLA	Shen, Kaini,et al."Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis".132(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。